<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROAMATINE- midodrine hydrochloride tablet </strong><br>Shire US Manufacturing Inc.<br></p></div>
<h1>
<span class="Bold">ProAmatine<span class="Sup">®</span></span><br>(midodrine hydrochloride)<br>Tablets
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="splSectionBlackBox"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Warning: Because ProAmatine<span class="Sup">®</span> can cause marked elevation of supine blood pressure, it should be used in patients whose lives are considerably impaired despite standard clinical care. The indication for use of ProAmatine<span class="Sup">®</span> in the treatment of symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> is based primarily on a change in a surrogate marker of effectiveness, an increase in systolic blood pressure measured one minute after standing, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits of ProAmatine<span class="Sup">®</span>, principally improved ability to carry out activities of daily living, have not been verified.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionDescription"></a><a name="section-1"></a><p></p>
<h1>
DESCRIPTION
</h1>
<p class="First"><span class="Bold">Name: ProAmatine<span class="Sup">®</span></span>(midodrine hydrochloride) Tablets</p>
<p><span class="Bold">Dosage Form:</span> 2.5-mg, 5-mg and 10-mg tablets for oral administration</p>
<p><span class="Bold">Active Ingredient:</span> Midodrine hydrochloride, 2.5 mg, 5 mg and 10 mg</p>
<p><span class="Bold">Inactive Ingredients:</span> Colloidal Silicone Dioxide NF, Corn Starch NF, FD&amp;C Blue No. 2 Lake (10-mg tablets), FD&amp;C Yellow No. 6 Lake (5-mg tablet), Magnesium Stearate NF, Microcrystalline Cellulose NF, Talc USP </p>
<p><span class="Bold">Pharmacological Classification:</span> Vasopressor/Antihypotensive</p>
<p>Chemical Names (USAN: Midodrine Hydrochloride): (1) Acetamide, 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]-monohydrochloride, (±)-;</p>
<p>(2) (±)-2-amino-N-(β-hydroxy-2,5-dimethoxyphenethyl)acetamide monohydrochloride</p>
<p>BAN, INN, JAN: Midodrine</p>
<p><span class="Bold">Structural formula:</span></p>
<div class="Figure"><img alt="
proamatine-structure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=171543e7-a592-4676-88ef-d68f14701d13&amp;name=proamatine-structure.jpg"></div>
<p><span class="Bold">Molecular formula:</span> C<span class="Sub">12</span>H<span class="Sub">18</span>N<span class="Sub">2</span>O<span class="Sub">4</span>HCl;    <span class="Bold">Molecular Weight:</span> 290.7</p>
<p><span class="Bold">Organoleptic Properties:</span> Odorless, white, crystalline powder</p>
<p><span class="Bold">Solubility:</span> Water:	Soluble</p>
<p>	       Methanol: Sparingly soluble </p>
<p><span class="Bold">pKa:</span> 7.8 (0.3% aqueous solution)  <span class="Bold">pH:</span> 3.5 to 5.5 (5% aqueous solution)</p>
<p><span class="Bold">Melting Range:</span> 200 to 203°C</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionClinicalPharmacology"></a><a name="section-2"></a><p></p>
<h1>
CLINICAL PHARMACOLOGY
</h1>
<p class="First"><span class="Bold">Mechanism of Action: ProAmatine</span><span class="Sup">®</span> forms an active metabolite, desglymidodrine, that is an alpha<span class="Sub">1</span>-agonist, and exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure. Desglymidodrine does not stimulate cardiac beta-adrenergic receptors. Desglymidodrine diffuses poorly across the blood-brain barrier, and is therefore not associated with effects on the central nervous system.</p>
<p>Administration of <span class="Bold">ProAmatine</span><span class="Sup">®</span> results in a rise in standing, sitting, and supine systolic and diastolic blood pressure in patients with <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> of various etiologies. Standing systolic blood pressure is elevated by approximately 15 to 30 mmHg at 1 hour after a 10-mg dose of midodrine, with some effect persisting for 2 to 3 hours. <span class="Bold">ProAmatine</span><span class="Sup">®</span> has no clinically significant effect on standing or supine pulse rates in patients with autonomic failure.</p>
<p><span class="Bold">Pharmacokinetics:</span><span class="Bold">ProAmatine</span><span class="Sup">®</span> is a prodrug, i.e., the therapeutic effect of orally administered midodrine is due to the major metabolite desglymidodrine, formed by deglycination of midodrine. After oral administration, <span class="Bold">ProAmatine</span><span class="Sup">®</span> is rapidly absorbed. The plasma levels of the prodrug peak after about half an hour, and decline with a half-life of approximately 25 minutes, while the metabolite reaches peak blood concentrations about 1 to 2 hours after a dose of midodrine and has a half-life of about 3 to 4 hours. The absolute bioavailability of midodrine  (measured as desglymidodrine) is 93%. The bioavailability of desglymidodrine is not affected by food. Approximately the same amount of desglymidodrine is formed after intravenous and oral administration of midodrine. Neither midodrine nor desglymidodrine is bound to plasma proteins to any significant extent.</p>
<p><span class="Bold">Metabolism and Excretion:</span> Thorough metabolic studies have not been conducted, but it appears that deglycination of midodrine to desglymidodrine takes place in many tissues, and both compounds are metabolized in part by the liver. Neither midodrine nor desglymidodrine is a substrate for monoamine oxidase.</p>
<p>Renal elimination of midodrine is insignificant. The renal clearance of desglymidodrine is of the order of 385 mL/minute, most, about 80%, by active renal secretion. The actual mechanism of active secretion has not been studied, but it is possible that it occurs by the base-secreting pathway responsible for the secretion of several other drugs that are bases (see also <span class="Bold Underline"><a href="#splSection1">Potential for Drug Interactions</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="splSectionClinicalStudies"></a><a name="section-3"></a><p></p>
<h1>
Clinical Studies
</h1>
<p class="First">Midodrine has been studied in 3 principal controlled trials, one of 3-weeks duration and 2 of 1 to 2 days duration. All studies were randomized, double-blind and parallel-design trials in patients with <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> of any etiology and supine-to-standing <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> of systolic blood pressure of at least 15 mmHg accompanied by at least moderate <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>. Patients with pre-existing sustained supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> above 180/110 mmHg were routinely excluded. In a 3-week study in 170 patients, most previously untreated with midodrine, the midodrine-treated patients (10 mg t.i.d., with the last dose not later than 6 P.M.) had significantly higher (by about 20 mmHg) 1-minute standing systolic pressure 1 hour after dosing (blood pressures were not measured at other times) for all 3 weeks. After week 1, midodrine-treated patients had small improvements in <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>/<span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span> scores and global evaluations, but these effects were made difficult to interpret by a high early drop-out rate (about 25% vs 5% on placebo). Supine and sitting blood pressure rose 16/8 and 20/10 mmHg, respectively, on average.</p>
<p>In a 2-day study, after open-label midodrine, known midodrine responders received midodrine 10 mg or placebo at 0, 3, and 6 hours. One-minute standing systolic blood pressures were increased 1 hour after each dose by about 15 mmHg and 3 hours after each dose by about 12mmHg; 3-minute standing pressures were increased also at 1, but not 3, hours after dosing. There were increases in standing time seen intermittently 1 hour after dosing, but not at 3 hours.</p>
<p>In a 1-day, dose-response trial, single doses of 0, 2.5, 10, and 20 mg of midodrine were given to 25 patients. The 10- and 20-mg doses produced increases in standing 1- minute systolic pressure of about 30 mmHg at 1 hour; the increase was sustained in part for 2 hours after 10 mg and 4 hours after 20 mg. Supine systolic pressure was =200 mmHg in 22% of patients on 10mg and 45% of patients on 20 mg; elevated pressures often lasted 6 hours or more.</p>
<p><span class="Bold">Special Populations</span></p>
<p>A study with 16 patients undergoing hemodialysis demonstrated that <span class="Bold">ProAmatine</span><span class="Sup">®</span> is removed by dialysis.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionIndicationsUsage"></a><a name="section-4"></a><p></p>
<h1>
INDICATIONS AND USAGE
</h1>
<p class="First"><span class="Bold">ProAmatine</span><span class="Sup">®</span> is indicated for the treatment of symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (OH). Because <span class="Bold">ProAmatine</span><span class="Sup">®</span> can cause marked elevation of supine blood pressure (BP&gt;200 mmHg systolic), it should be used in patients whose lives are considerably impaired despite standard clinical care, including non-pharmacologic treatment (such as support stockings), fluid expansion, and lifestyle alterations. The indication is based on <span class="Bold">ProAmatine</span><span class="Sup">®</span>'s effect on increases in 1-minute standing systolic blood pressure, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits of <span class="Bold">ProAmatine</span><span class="Sup">®</span>, principally improved ability to perform life activities, have not been established. Further clinical trials are underway to verify and describe the clinical benefits of <span class="Bold">ProAmatine</span><span class="Sup">®</span>.</p>
<p>After initiation of treatment, <span class="Bold">ProAmatine</span><span class="Sup">®</span> should be continued only for patients who report significant symptomatic improvement.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionContraindications"></a><a name="section-5"></a><p></p>
<h1>
CONTRAINDICATIONS
</h1>
<p class="First"><span class="Bold">ProAmatine</span><span class="Sup">®</span> is contraindicated in patients with severe organic heart disease, acute <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> or <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span>. <span class="Bold">ProAmatine<span class="Sup">®</span></span> should not be used in patients with persistent and excessive supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="splSectionWarnings"></a><a name="section-6"></a><p></p>
<h1>
WARNINGS
</h1>
<p class="First"><span class="Bold">Supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>: The most potentially serious adverse reaction associated with ProAmatine</span><span class="Sup">®</span><span class="Bold"> therapy is marked elevation of supine arterial blood pressure (supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>). Systolic pressure of about 200 mmHg were seen overall in about 13.4% of patients given 10 mg of ProAmatine</span><span class="Sup">®</span><span class="Bold">. Systolic elevations of this degree were most likely to be observed in patients with relatively elevated pre-treatment systolic blood pressures (mean 170 mmHg). There is no experience in patients with initial supine systolic pressure above 180 mmHg, as those patients were excluded from the clinical trials. Use of ProAmatine</span><span class="Sup">®</span><span class="Bold"> in such patients is not recommended. Sitting blood pressures were also elevated by ProAmatine</span><span class="Sup">®</span><span class="Bold"> therapy. It is essential to monitor supine and sitting blood pressures in patients maintained on ProAmatine</span><span class="Sup">®</span><span class="Bold">.</span></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="splSectionPrecautions"></a><a name="section-7"></a><p></p>
<h1>
PRECAUTIONS
</h1>
<p class="First"><span class="Bold"></span></p>
<div class="Section" data-sectionCode="34072-9">
<a name="splSectionPrecautionsGeneral"></a><a name="section-7.1"></a><p></p>
<h2>
General
</h2>
<p class="First">The potential for supine and sitting <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> should be evaluated at the beginning of <span class="Bold">ProAmatine</span><span class="Sup">® </span>therapy. Supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> can often be controlled by preventing the patient from becoming fully supine, i.e., sleeping with the head of the bed elevated. The patient should be cautioned to report symptoms of supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> immediately. Symptoms may include cardiac awareness, pounding in the ears, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, etc. The patient should be advised to discontinue the medication immediately if supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> persists.</p>
<p>Blood pressure should be monitored carefully when <span class="Bold">ProAmatine</span><span class="Sup">®</span> is used concomitantly with other agents that cause <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, such as phenylephrine, ephedrine, dihydroergotamine, phenylpropanolamine, or pseudoephedrine.</p>
<p>A slight slowing of the heart rate may occur after administration of <span class="Bold">ProAmatine</span><span class="Sup">®</span>, primarily due to vagal reflex. Caution should be exercised when <span class="Bold">ProAmatine</span><span class="Sup">®</span> is used concomitantly with cardiac glycosides (such as digitalis), psychopharmacologic agents, beta blockers or other agents that directly or indirectly reduce heart rate. Patients who experience any signs or symptoms suggesting <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (pulse slowing, increased <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, cardiac awareness) should be advised to discontinue <span class="Bold">ProAmatine</span><span class="Sup">®</span> and should be re-evaluated.</p>
<p><span class="Bold">ProAmatine</span><span class="Sup">®</span> should be used cautiously in patients with <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> problems, as desglymidodrine acts on the alpha-adrenergic receptors of the bladder neck.</p>
<p><span class="Bold">ProAmatine</span><span class="Sup">®</span> should be used with caution in orthostatic hypotensive patients who are also diabetic, as well as those with a history of visual problems who are also taking fludrocortisone acetate, which is known to cause an increase in intraocular pressure and <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. </p>
<p><span class="Bold">ProAmatine</span><span class="Sup">®</span> use has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Because desglymidodrine is eliminated via the kidneys, and higher blood levels would be expected in such patients, <span class="Bold">ProAmatine</span><span class="Sup">®</span> should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, with a starting dose of 2.5 mg (see <span class="Bold Underline"><a href="#splSectionDosageAdministration">DOSAGE AND ADMINISTRATION</a></span>). Renal function should be assessed prior to initial use of <span class="Bold">ProAmatine</span><span class="Sup">®</span>.</p>
<p><span class="Bold">ProAmatine</span><span class="Sup">®</span> use has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. <span class="Bold">ProAmatine</span><span class="Sup">®</span> should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, as the liver has a role in the metabolism of midodrine.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPrecautionsPatientInfo"></a><a name="section-7.2"></a><p></p>
<h2>
Information for Patients
</h2>
<p class="First">Patients should be told that certain agents in over-the-counter products, such as <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> remedies and diet aids, can elevate blood pressure, and therefore, should be used cautiously with <span class="Bold">ProAmatine</span><span class="Sup">®</span>, as they may enhance or potentiate the pressor effects of <span class="Bold">ProAmatine</span><span class="Sup">®</span>  (see <span class="Bold Underline"><a href="#splSectionPrecautionsDrugInteract">Drug Interactions</a></span>). Patients should also be made aware of the possibility of supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. They should be told to avoid taking their dose if they are to be supine for any length of time, i.e., they should take their last daily dose of <span class="Bold">ProAmatine</span><span class="Sup">®</span> 3 to 4 hours before bedtime to minimize nighttime supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="splSectionPrecautionsLabInfo"></a><a name="section-7.3"></a><p></p>
<h2>
Laboratory Tests
</h2>
<p class="First">Since desglymidodrine is eliminated by the kidneys and the liver has a role in its metabolism, evaluation of the patient should include assessment of renal and hepatic function prior to initiating therapy and subsequently, as appropriate.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="splSectionPrecautionsDrugInteract"></a><a name="section-7.4"></a><p></p>
<h2>
Drug Interactions
</h2>
<p class="First">When administered concomitantly with <span class="Bold">ProAmatine</span><span class="Sup">®</span>, cardiac glycosides may enhance or precipitate <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, A.V. block or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>.</p>
<p>The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of <span class="Bold">ProAmatine</span><span class="Sup">®</span>. Therefore, caution should be used when <span class="Bold">ProAmatine</span><span class="Sup">®</span> is administered concomitantly with agents that cause <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>.</p>
<p><span class="Bold">ProAmatine</span><span class="Sup">®</span> has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. The potential for supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> should be carefully monitored in these patients and may be minimized by either reducing the dose of fludrocortisone acetate or decreasing the salt intake prior to initiation of treatment with <span class="Bold">ProAmatine</span><span class="Sup">®</span>. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <span class="Bold">ProAmatine</span><span class="Sup">®</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection1"></a><a name="section-7.5"></a><p></p>
<h2>
Potential for Drug Interaction
</h2>
<p class="First">It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. Thus there may be a potential for drug-drug interactions with these drugs.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPrecautionsCarcinogen"></a><a name="section-7.6"></a><p></p>
<h2>
Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Long-term studies have been conducted in rats and mice at dosages 3 to 4 times the maximum recommended daily human dose on a mg/m<span class="Sup">2</span> basis, with no indication of carcinogenic effects related to <span class="Bold">ProAmatine</span><span class="Sup">®</span>. Studies investigating the mutagenic potential of <span class="Bold">ProAmatine</span><span class="Sup">®</span> revealed no evidence of mutagenicity.  Other than the dominant lethal assay in male mice, where no impairment of fertility was observed, there have been no studies on the effects of <span class="Bold">ProAmatine</span><span class="Sup">®</span> on fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPrecautionsPregnancy"></a><a name="section-7.7"></a><p></p>
<h2>
Pregnancy
</h2>
<p class="First"><span class="Italics">Pregnancy Category C</span>. <span class="Bold">ProAmatine</span><span class="Sup">®</span> increased the rate of embryo resorption, reduced fetal body weight in rats and rabbits, and decreased fetal survival in rabbits when given in doses 13 (rat) and 7 (rabbit) times the maximum human dose based on body surface area (mg/m<span class="Sup">2</span>). There are no adequate and well-controlled studies in pregnant women. <span class="Bold">ProAmatine</span><span class="Sup">®</span> should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. No teratogenic effects have been observed in studies in rats and rabbits.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPrecautionsPregnancyNursing"></a><a name="section-7.8"></a><p></p>
<h2>
Nursing Mothers
</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when <span class="Bold">ProAmatine<span class="Sup">®</span></span> is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPrecautionsPediatric"></a><a name="section-7.9"></a><p></p>
<h2>
Pediatric Use
</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionAdverseReactions"></a><a name="section-8"></a><p></p>
<h1>
ADVERSE REACTIONS
</h1>
<p class="First">The most frequent adverse reactions seen in controlled trials were supine and sitting <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, mainly of the scalp; goosebumps; <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>; urinary urge; <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> and <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>. </p>
<p>The frequency of these events in a 3-week placebo-controlled trial is shown in the following table:</p>
<table width="80%">
<caption><span>
Adverse Events
</span></caption>
<col align="left" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule" align="center"></th>
<th class="Botrule Lrule Rrule" align="center" colspan="2">
<span class="Bold">Placebo</span><br>n=88
</th>
<th class="Botrule Lrule Rrule" align="center" colspan="2">
<span class="Bold">Midodrine</span><br>n=82
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="center"><span class="Bold">Event</span></th>
<th class="Botrule Lrule Rrule" align="center"><span class="Bold"># of reports</span></th>
<th class="Botrule Lrule Rrule" align="center"><span class="Bold">% of patients</span></th>
<th class="Botrule Lrule Rrule" align="center"><span class="Bold"># of reports</span></th>
<th class="Botrule Lrule Rrule" align="center"><span class="Bold">% of patients</span></th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left">
Total # of reports
</td>
<td class="Botrule Lrule Rrule" align="center">
22
</td>
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Lrule Rrule" align="center">
77
</td>
<td class="Botrule Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span><span class="Sup">1</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
4
</td>
<td class="Botrule Lrule Rrule" align="center">
4.5
</td>
<td class="Botrule Lrule Rrule" align="center">
15
</td>
<td class="Botrule Lrule Rrule" align="center">
18.3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4224957" conceptname="Piloerection">Piloerection</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
0
</td>
<td class="Botrule Lrule Rrule" align="center">
0
</td>
<td class="Botrule Lrule Rrule" align="center">
11
</td>
<td class="Botrule Lrule Rrule" align="center">
13.4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span><span class="Sup">2</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
0
</td>
<td class="Botrule Lrule Rrule" align="center">
0
</td>
<td class="Botrule Lrule Rrule" align="center">
11
</td>
<td class="Botrule Lrule Rrule" align="center">
13.4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
Pruritis<span class="Sup">3</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
2
</td>
<td class="Botrule Lrule Rrule" align="center">
2.3
</td>
<td class="Botrule Lrule Rrule" align="center">
10
</td>
<td class="Botrule Lrule Rrule" align="center">
12.2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
Supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span><span class="Sup">4</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
0
</td>
<td class="Botrule Lrule Rrule" align="center">
0
</td>
<td class="Botrule Lrule Rrule" align="center">
6
</td>
<td class="Botrule Lrule Rrule" align="center">
7.3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
0
</td>
<td class="Botrule Lrule Rrule" align="center">
0
</td>
<td class="Botrule Lrule Rrule" align="center">
4
</td>
<td class="Botrule Lrule Rrule" align="center">
4.9
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span><span class="Sup">5</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
0
</td>
<td class="Botrule Lrule Rrule" align="center">
0
</td>
<td class="Botrule Lrule Rrule" align="center">
4
</td>
<td class="Botrule Lrule Rrule" align="center">
4.9
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
1
</td>
<td class="Botrule Lrule Rrule" align="center">
1.1
</td>
<td class="Botrule Lrule Rrule" align="center">
2
</td>
<td class="Botrule Lrule Rrule" align="center">
2.4
</td>
</tr>
</tbody>
</table>
<p><span class="Sup">1</span> Includes <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span> and scalp <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span></p>
<p><span class="Sup">2</span> Includes <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span> (1), <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">increased urinary frequency</span> (2), impaired urination (1), <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> (5), <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">urinary urgency</span> (2)</p>
<p><span class="Sup">3</span> Includes scalp <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
<p><span class="Sup">4</span> Includes patients who experienced an increase in supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span></p>
<p><span class="Sup">5</span> Includes <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> increase</p>
<p>Less frequent adverse reactions were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; feeling of pressure/fullness in the head; vasodilation/<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> face; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>/thinking abnormality; <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>; <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>/<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Other adverse reactions that occurred rarely were <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; skin <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>; <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>; <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>; <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>; canker sore; <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>; <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>; impaired urination; <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>; <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>; <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">pyrosis</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; gastrointestinal distress; <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>. </p>
<p>The most potentially serious adverse reaction associated with <span class="Bold">ProAmatine<span class="Sup">®</span></span> therapy is supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. The feelings of <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4224957" conceptname="Piloerection">piloerection</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> are pilomotor reactions associated with the action of midodrine on the alpha-adrenergic receptors of the hair follicles. Feelings of <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">urinary urgency</span>, retention and frequency are associated with the action of midodrine on the alpha-receptors of the bladder neck.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="splSectionOverdose"></a><a name="section-9"></a><p></p>
<h1>
OVERDOSAGE
</h1>
<p class="First">Symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> could include <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4224957" conceptname="Piloerection">piloerection</span> (goosebumps), a sensation of <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">coldness</span> and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. There are 2 reported cases of overdosage with <span class="Bold">ProAmatine<span class="Sup">®</span></span>, both in young males. One patient ingested <span class="Bold">ProAmatine<span class="Sup">®</span></span> drops, 250 mg, experienced systolic blood pressure greater than 200 mmHg, was treated with an IV injection of 20 mg of phentolamine, and was discharged the same night without any complaints. The other patient ingested 205 mg of <span class="Bold">ProAmatine<span class="Sup">®</span></span> (41 5-mg tablets), and was found <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargic</span> and unable to talk, unresponsive to voice but responsive to painful stimuli, hypertensive and bradycardic. Gastric lavage was performed, and the patient recovered fully by the next day without sequelae.</p>
<p>The single doses that would be associated with symptoms of overdosage or would be potentially life-threatening are unknown. The oral LD<span class="Sub">50</span> is approximately 30 to 50 mg/kg in rats, 675 mg/kg in mice, and 125 to 160 mg/kg in dogs.</p>
<p>Desglymidodrine is dialyzable.</p>
<p>Recommended general treatment, based on the pharmacology of the drug, includes induced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and administration of alpha-sympatholytic drugs (e.g., phentolamine).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionDosageAdministration"></a><a name="section-10"></a><p></p>
<h1>
DOSAGE AND ADMINISTRATION
</h1>
<p class="First">The recommended dose of <span class="Bold">ProAmatine<span class="Sup">®</span></span> is 10 mg, 3 times daily. Dosing should take place during the daytime hours when the patient needs to be upright, pursuing the activities of daily living. A suggested dosing schedule of approximately 4-hour intervals is as follows: shortly before, or upon arising in the morning, midday and late afternoon (not later than 6 P.M.). Doses may be given in 3-hour intervals, if required, to control symptoms, but not more frequently. Single doses as high as 20 mg have been given to patients, but severe and persistent systolic supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> occurs at a high rate (about 45%) at this dose. In order to reduce the potential for supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> during sleep, <span class="Bold">ProAmatine<span class="Sup">®</span></span> should not be given after the evening meal or less than 4 hours before bedtime. Total daily doses greater than 30 mg have been tolerated by some patients, but their safety and usefulness have not been studied systematically or established. Because of the risk of supine <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="Bold">ProAmatine<span class="Sup">®</span></span> should be continued only in patients who appear to attain symptomatic improvement during initial treatment.</p>
<p>The supine and standing blood pressure should be monitored regularly, and the administration of <span class="Bold">ProAmatine<span class="Sup">®</span></span> should be stopped if supine blood pressure increases excessively.</p>
<p>Because desglymidodrine is excreted renally, dosing in patients with abnormal renal function should be cautious; although this has not been systematically studied, it is recommended that treatment of these patients be initiated using 2.5-mg doses.</p>
<p>Dosing in children has not been adequately studied. </p>
<p>Blood levels of midodrine and desglymidodrine were similar when comparing levels in patients 65 or older vs. younger than 65 and when comparing males vs. females, suggesting dose modifications for these groups are not necessary.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionHowSupplied"></a><a name="section-11"></a><p></p>
<h1>
HOW SUPPLIED
</h1>
<p class="First"><span class="Bold">ProAmatine<span class="Sup">®</span></span> is supplied as 2.5-mg, 5-mg and 10-mg tablets for oral administration. The 2.5-mg tablet is white, round, and biplanar, with a bevelled edge, and is scored on one side with "RPC" above and "2.5" below the score, and "003" on the other side. The 5-mg tablet is orange, round, and biplanar, with a bevelled edge, and is scored on one side with "RPC" above and "5" below the score, and "004" on the other side. The 10-mg is blue, round, and biplanar, with a bevelled edge, and is scored on one side with "RPC" above and "10" below the score, and "007" on the other side.</p>
<p>2.5-milligram Tablets:	NDC 54092-003-01	Bottle of 100</p>
<p>5.0-milligram Tablets:	NDC 54092-004-01	Bottle of 100</p>
<p>10-milligram Tablets:	NDC 54092-007-01	Bottle of 100</p>
<p><span class="Bold">Store at 25°C (77°F)</span></p>
<p><span class="Bold">Excursions permitted to 15-30 °C (59-86 °F)</span></p>
<p><span class="Bold">[see USP Controlled Room Temperature]</span></p>
<p>Manufactured for </p>
<p><span class="Bold">Shire US Inc.</span>, One Riverfront Place, Newport, KY, 41071, USA</p>
<p>by NYCOMED Austria GmbH</p>
<p>© 2003 Shire US Inc.</p>
<p>Rev. 10/03</p>
<p>003 0107 006</p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-12"></a><p></p>
<h1>
Container Labels
</h1>
<p class="First">2.5mg Bottle Label</p>
<div class="Figure"><img alt="
bottle-2-5mg
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=171543e7-a592-4676-88ef-d68f14701d13&amp;name=bottle-2-5mg.jpg"></div>
<p>5mg Bottle Label</p>
<div class="Figure"><img alt="
bottle-5mg
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=171543e7-a592-4676-88ef-d68f14701d13&amp;name=bottle-5mg.jpg"></div>
<p>10mg Bottle Label</p>
<div class="Figure"><img alt="
bottle-10mg
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=171543e7-a592-4676-88ef-d68f14701d13&amp;name=bottle-10mg.jpg"></div>
<p>2.5mg Carton Label</p>
<div class="Figure"><img alt="
carton-2-5mg
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=171543e7-a592-4676-88ef-d68f14701d13&amp;name=carton-2-5mg.jpg"></div>
<p>5mg Carton Label</p>
<div class="Figure"><img alt="
carton-5mg
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=171543e7-a592-4676-88ef-d68f14701d13&amp;name=carton-5mg.jpg"></div>
<p>10mg Carton Label</p>
<div class="Figure"><img alt="
carton-10mg
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=171543e7-a592-4676-88ef-d68f14701d13&amp;name=carton-10mg.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROAMATINE 		
					</strong><br><span class="contentTableReg">midodrine hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54092-003</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MIDODRINE HYDROCHLORIDE</strong> (MIDODRINE) </td>
<td class="formItem">MIDODRINE HYDROCHLORIDE</td>
<td class="formItem">2.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RPC;2;5;003</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54092-003-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019815</td>
<td class="formItem">09/06/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROAMATINE 		
					</strong><br><span class="contentTableReg">midodrine hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54092-004</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MIDODRINE HYDROCHLORIDE</strong> (MIDODRINE) </td>
<td class="formItem">MIDODRINE HYDROCHLORIDE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange (orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RPC;5;004</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54092-004-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019815</td>
<td class="formItem">09/06/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROAMATINE 		
					</strong><br><span class="contentTableReg">midodrine hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54092-007</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MIDODRINE HYDROCHLORIDE</strong> (MIDODRINE) </td>
<td class="formItem">MIDODRINE HYDROCHLORIDE</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue (blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RPC;10;007</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54092-007-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019815</td>
<td class="formItem">03/20/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Shire US Manufacturing Inc.
							(964907406)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Shire US Inc. (622467447)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Nycomed Austria GmbH</td>
<td class="formItem"></td>
<td class="formItem">300689002</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>735f8aae-18a5-4120-a0b7-369af3e58c6a</div>
<div>Set id: 171543e7-a592-4676-88ef-d68f14701d13</div>
<div>Version: 2</div>
<div>Effective Time: 20091008</div>
</div>
</div> <div class="DistributorName">Shire US Manufacturing Inc.</div></p>
</body></html>
